Pulmonary Arterial Hypertension in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market.
Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
Scope
This publication is an expanded version of the Excel model containing the patient-based forecast sales for PAH, covered in GlobalData’s report “Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034”, published in June 2025. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Acceleron Pharma Inc
Actelion
Amgen Inc
Bayer AG
Bristol Myers Squibb
Eli Lilly and Co
Entera Bio Ltd
Gilead Sciences Inc
GlaxoSmithKline
Johnson & Johnson
Merck & Co Inc
Novartis International AG
Pfizer Inc
Roche Holding AG
Sanofi
Teva Pharmaceutical Industries Ltd
UCB S.A.
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pulmonary Arterial Hypertension reports